Fresh analysis indicates that individuals who come off blockbuster GLP-1 drugs like semaglutide or tirzepatide tend to recover reduced body mass much more quickly than those who halt conventional diet and exercise programs.
Research printed in a prominent health publication points out that while obese people often shed a large proportion of their body weight while undergoing treatment, the mass comes back at an estimated rate of nearly a kilo each month after stopping.
"Individuals using such treatments should be informed of the risk of fast rebound weight gain when the medication is stopped," warns expert Dr. Susan Jebb.
Such speed of recovery means a return to pre-treatment mass within about one and a half years.
Weighing Therapies
The research, which examined 37 of studies involving thousands of participants, compared the results of GLP-1 agonists with other pills.
Scientists point out that people who lose weight through lifestyle changes alone generally see a more gradual weight regain—perhaps 0.1 kg a month—post-intervention.
The Reason for the Fast Rebound
Experts suggest the mechanism of the injections accounts for the accelerated weight return.
GLP-1 drugs imitate a body's own chemical called glucagon-like peptide-1, which moderates appetite.
"Sustained high doses of GLP-1 levels far above than the body's typical production may cause the system to generate a reduced amount of its endogenous GLP-1, and could diminish sensitivity to its effects," noted Dr. Adam Collins, a nutrition expert.
"Discontinuation of this hormone supplement results in hunger is unsuppressed, making excessive eating far more likely."
A Lifelong Issue?
Health authorities advise the injections for individuals with obesity-related health risks, alongside recommended diet and exercise modifications.
Professionals say that, due to the high risk of weight regain, the therapy might need to be long-term.
This opinion is supported by drug manufacturers, who note that the findings "highlight the chronic nature of obesity," similar to managing conditions like high blood pressure.
Patient Accounts
Individuals who have discontinued the medication describe a intense return of appetite.
"It was like a trigger activating and I was suddenly ravenous," described a patient.
The struggle is compounded if patients have not established lasting dietary or behavioural changes during treatment.
Growing Adoption
Figures indicate that millions of adults in the UK have used weight-loss jabs in the past year, with desire being substantial.
- Adoption is greater among females compared to men.
- The middle-aged age group shows the highest level of interest.
- Many access the drugs through private healthcare rather than the NHS.
Finally, clinicians emphasize that while the jabs are effective tools for shedding pounds, they are not a standalone cure and lasting health benefits likely depends on ongoing behavioural support.
